Navigation Links
Global Scientific Research Collaboration Leads to Breakthrough in Culturing HEK 293 Cells in Animal-free Media
Date:10/28/2008

Joint study between leading researchers in academia and industry from US, Australian and European Researchers leads to discovery of method for promoting HEK 293 cell growth and productivity using protein derived from colostrum.

Fort Collins, CO (PRWEB) October 28, 2008 -- A recent breakthrough was published in the scientific journal In Vitro Cellular & Developmental Biology showing the benefit of using recombinant lactoferrin (Lacromin) to promote growth of HEK 293 cells using a serum-free and animal-free media. Lactoferrin is a protein derived from colostrum and has been made using recombinant techniques in an animal-free system by InVitria (see Lacromin). HEK 293 cells are used by biotechnology and biopharmaceutical companies to produce human therapeutics.

The peer-reviewed study showed that recombinant lactoferrin (Lacromin) was used as a serum-free and animal-free media component to enhance the growth of a variety of cell lines, including HEK cell lines. Using recombinant human lactoferrin (Lacromin), viable cell growth was considerably higher when compared to using recombinant or native human transferrin. The study also showed that recombinant human lactoferrin (Lacromin) was capable of promoting HEK293 cell growth faster than human transferrin, leading to faster doubling times.

Dr. Ning Huang, Vice President of Research and Development for InVitria, coordinated the study entitled, "Bioactive recombinant human lactoferrin, derived from rice, stimulates mammalian cell growth."

"This research supports the use of recombinant human lactoferrin for biopharmaceutical production companies that are currently using HEK 293 cells," said Dr. Huang. He continued, "Since recombinant lactoferrin is well defined and animal free, it is ideal for use in serum free or defined media to deliver a critical growth factor for HEK 293 cells."

Dr. Huang concluded, "This finding will lead to improved growth and performance of HEK 293 cell lines in animal free and defined media, leading to safer and more efficient biopharmaceutical production."

Research institutions from around the world were involved in this discovery including: University of Auckland in New Zealand and Barts & The London Queen Mary's School of Medicine & Dentistry in London. Also, cell culture industry researchers at HyClone, KC Bio and InVitria contributed to these findings.

About InVitria (InVitria)
InVitria has developed defined and animal free cell culture media components that enhance productivity, safety and time to market for companies in the biopharmaceutical, mammalian cell culture, regenerative medicine, cell therapy, stem cell and diagnostics industry. InVitria's recombinant human lactoferrin called Lacromin was utilized in this study. InVitria also produces other animal free and defined media components including recombinant albumin (Cellastim).

For more detailed product information requests or to order re-prints of the above-mentioned article contact InVitria by e-mail or phone.

E-mail: info @ InVitria.com
Phone: 1-800-916-8311

###

Read the full story at http://www.prweb.com/releases/HEK293cells/recombinantlactoferrin/prweb1535054.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic ... treatments to both new and existing patients. Cosmetic dentistry allows patients to improve the ... have healthy smiles with some minor or more serious cosmetic flaws. These specials allow ...
(Date:5/3/2016)... ... May 03, 2016 , ... Celestix ... announced the new SecureAccess feature for its CelestixEdge solution. CelestixEdge is the ... enable organizations to get the DirectAccess user experience on unsupported DirectAccess clients ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... helps healthcare organizations, especially medium and small physician practices, to better grasp and ... unique step-by-step approach that guides practices on a well-defined, expert-created path to compliance. ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK Products, Inc. (RNK) ... software that enables the stethoscope stream to go over the video conferencing audio ... flagship PCP-USB stethoscope. , Remote auscultation involves two software elements on the PC: ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research ... issue representing international (non-US) based authors, the third volume of PXJ continues to ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... the EMR (Electronic Medical Records) market in a recent ... International sales, vendor switches, Increased physician usage, a growing market ... trends were noted in Kalorama,s report EMR ... The report marks Kalorama,s seventh complete study of the ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
Breaking Medicine Technology: